Trial Profile
A study phase IIa study of RX-3117 in combination with cisplatin in patients with metastatic bladder cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2021
Price :
$35
*
At a glance
- Drugs Roducitabine (Primary) ; Cisplatin
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Aug 2017 New trial record
- 07 Aug 2017 According to a Rexahn Pharmaceuticals media release, this trial is expected to initiated in second half of 2017.